Start-Up Spotlight: Aria CV Addresses Right-Heart Failure With Purely Mechanical Solution
Executive Summary
St. Paul-based Aria CV is developing a "passive" pulmonary artery balloon system to treat pulmonary hypertension and impede the development of heart failure. Following a successful first-in-human study, the company is currently developing a feasibility study it expects will lead to a US pivotal trial in several years.
You may also be interested in...
QUOTED. Dec. 4, 2018. John Scandurra.
Aria CV hopes to address pulmonary hypertension, a potential devastating condition that currently has few treatments, with a unique balloon device that requires no power supply, battery, pump, or synchronization. See what Aria CEO John Scandurra said about it here.
New MDIC CEO Talks NEST, Case For Quality, CMS, And More
Two months into the job, Medical Device Innovation Consortium CEO Pamela Goldberg talks about the organization's work running the NEST Coordinating Center, its efforts to engage the Medicare agency, early feasibility studies and its work with US FDA on Case for Quality.
Medtronic Hires New Neuromodulation Leader
Paolo Di Vincenzo, the general manager of Smith+Nephew's US advanced wound management business will join Medtronic as the president of its neuromodulation business.